NCT01160185已完成不适用
Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1
- 主要终点
- Survival
研究概览
简要总结
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix
详细描述
Studies included in the meta-analysis were: GOG-0179, GOG-0204 & GOG-0169
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Randomised Clinical Trials or systematic reviews or meta-analyses
- •Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease
排除标准
- 未提供
研究组 & 干预措施
cisplatin
干预措施: cisplatin (Drug)
cisplatin + topotecan
干预措施: cisplatin (Drug)
cisplatin + topotecan
干预措施: topotecan (Drug)
cisplatin + paclitaxel
干预措施: paclitaxel (Drug)
cisplatin + paclitaxel
干预措施: cisplatin (Drug)
结局指标
主要结局
Survival
时间窗: 12 months
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialEpithelial Ovarian CancerNCT01630018Chong Kun Dang Pharmaceutical141
已完成
2 期
Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancerJPRN-C000000130Okayama Lung Cancer Study Group30
已完成
3 期
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer TherapyOvarian CancerNCT00312988North Eastern German Society of Gynaecological Oncology450
已完成
2 期
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerPeritoneal CancerNeoplasms, OvarianFallopian Tube CancerOvarian CancerNCT00061308GlaxoSmithKline75
终止
早期 1 期
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV GliomaGlioma of BrainNCT03927274H. Lee Moffitt Cancer Center and Research Institute3